CovidSeniorV1, Main, Curation, bibRecord, 000375

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.

Identifieur interne : 000375 ( Main/Curation ); précédent : 000374; suivant : 000376

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.

Auteurs : Thorsten Fuereder [Autriche] ; Anna Sophie Berghoff [Autriche] ; Gerwin Heller [Autriche] ; Helmuth Haslacher [Autriche] ; Thomas Perkmann [Autriche] ; Robert Strassl [Autriche] ; Julia Maria Berger [Autriche] ; Hannah Christina Puhr [Autriche] ; Judith Kreminger [Autriche] ; Florian Moik [Autriche] ; Lorenz Schubert [Autriche] ; Angelika Martina Starzer [Autriche] ; Ariane Steindl [Autriche] ; Stefan Winkler [Autriche] ; Matthias Preusser [Autriche] ; Selma Tobudic [Autriche]

Source :

ESMO open [ 2059-7029 ] ; 2020.

RBID : pubmed:32878898

Descripteurs français

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Viral (blood), Austria (epidemiology), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Biomarkers (blood), Clinical Laboratory Techniques (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (epidemiology), Coronavirus Infections (transmission), Coronavirus Infections (virology), Female (MeSH), Host-Pathogen Interactions (MeSH), Humans (MeSH), Male (MeSH), Medical Staff, Hospital (MeSH), Middle Aged (MeSH), Nursing Staff, Hospital (MeSH), Oncologists (MeSH), Oncology Nursing (MeSH), Oncology Service, Hospital (MeSH), Pandemics (MeSH), Patients (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (epidemiology), Pneumonia, Viral (transmission), Pneumonia, Viral (virology), Predictive Value of Tests (MeSH), Prospective Studies (MeSH), Reproducibility of Results (MeSH), Retrospective Studies (MeSH), Seroepidemiologic Studies (MeSH), Serologic Tests (MeSH), Tertiary Care Centers (MeSH), Young Adult (MeSH).
MESH :
- chemical , blood : Antibodies, Viral, Biomarkers.
- geographic , epidemiology : Austria.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus.
- pathogenicity : Betacoronavirus.
- transmission : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adolescent, Adult, Aged, Aged, 80 and over, Clinical Laboratory Techniques, Female, Host-Pathogen Interactions, Humans, Male, Medical Staff, Hospital, Middle Aged, Nursing Staff, Hospital, Oncologists, Oncology Nursing, Oncology Service, Hospital, Pandemics, Patients, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Retrospective Studies, Seroepidemiologic Studies, Serologic Tests, Tertiary Care Centers, Young Adult.

Abstract

BACKGROUND

During the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications for oncological care.

METHODS

HCP and patients with cancer at the Division of Oncology, Medical University of Vienna were included between 21 March and 4 June and tested for total antibodies against SARS-CoV-2 employing the Roche Elecsys Anti-SARS-CoV-2 immunoassay. Reactive samples were confirmed or disproved by the Abbott SARS-CoV-2 IgG test. Additionally, a structured questionnaire regarding basic demographic parameters, travel history and COVID-19-associated symptoms had to be completed by HCP.

RESULTS

146 subjects (62 HCP and 84 patients with cancer) were enrolled. In the oncological HCP cohort, 20 (32.3%) subjects were medical oncologists, 28 (45.2%) nurses at our ward and 14 (22.6%) fulfil other functions such as study coordinators. In the patient cohort, most individuals are on active anticancer treatment (96.4%). 26% of the HCP and 6% of the patients had symptoms potentially associated with COVID-19 since the end of February 2020. However, only in 2 (3.2%) HCP and in 3 (3.6%) patients, anti-SARS-Cov-2 total antibodies were detected. The second assay for anti-SARS-Cov-2 IgG antibodies confirmed the positive result in all HCP and in 2 (2.4%) patients, suggesting an initial assay's unspecific reaction in one case. In individuals with a confirmed test result, an active COVID-19 infection was documented by a positive SARS-CoV-2 RNA PCR test.

CONCLUSION

Specific anti-SARS-CoV-2 antibodies were found solely in persons after a documented SARS-CoV-2 viral infection, thus supporting the test methods' high sensitivity and specificity. The low prevalence of anti-SARS-CoV-2 antibodies in our cohorts indicates a lack of immunity against SARS-CoV-2. It highlights the need for continued strict safety measures to prevent uncontrolled viral spread among oncological HCPs and patients with cancer.

DOI: 10.1136/esmoopen-2020-000889
PubMed: 32878898
PubMed Central: PMC7470513

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000375

Links to Exploration step

pubmed:32878898

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.</title>
<author><name sortKey="Fuereder, Thorsten" sort="Fuereder, Thorsten" uniqKey="Fuereder T" first="Thorsten" last="Fuereder">Thorsten Fuereder</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Berghoff, Anna Sophie" sort="Berghoff, Anna Sophie" uniqKey="Berghoff A" first="Anna Sophie" last="Berghoff">Anna Sophie Berghoff</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Heller, Gerwin" sort="Heller, Gerwin" uniqKey="Heller G" first="Gerwin" last="Heller">Gerwin Heller</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Haslacher, Helmuth" sort="Haslacher, Helmuth" uniqKey="Haslacher H" first="Helmuth" last="Haslacher">Helmuth Haslacher</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Laboratory Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Perkmann, Thomas" sort="Perkmann, Thomas" uniqKey="Perkmann T" first="Thomas" last="Perkmann">Thomas Perkmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Laboratory Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Strassl, Robert" sort="Strassl, Robert" uniqKey="Strassl R" first="Robert" last="Strassl">Robert Strassl</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Laboratory Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Berger, Julia Maria" sort="Berger, Julia Maria" uniqKey="Berger J" first="Julia Maria" last="Berger">Julia Maria Berger</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Puhr, Hannah Christina" sort="Puhr, Hannah Christina" uniqKey="Puhr H" first="Hannah Christina" last="Puhr">Hannah Christina Puhr</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kreminger, Judith" sort="Kreminger, Judith" uniqKey="Kreminger J" first="Judith" last="Kreminger">Judith Kreminger</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moik, Florian" sort="Moik, Florian" uniqKey="Moik F" first="Florian" last="Moik">Florian Moik</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schubert, Lorenz" sort="Schubert, Lorenz" uniqKey="Schubert L" first="Lorenz" last="Schubert">Lorenz Schubert</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Starzer, Angelika Martina" sort="Starzer, Angelika Martina" uniqKey="Starzer A" first="Angelika Martina" last="Starzer">Angelika Martina Starzer</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Steindl, Ariane" sort="Steindl, Ariane" uniqKey="Steindl A" first="Ariane" last="Steindl">Ariane Steindl</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Winkler, Stefan" sort="Winkler, Stefan" uniqKey="Winkler S" first="Stefan" last="Winkler">Stefan Winkler</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Preusser, Matthias" sort="Preusser, Matthias" uniqKey="Preusser M" first="Matthias" last="Preusser">Matthias Preusser</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tobudic, Selma" sort="Tobudic, Selma" uniqKey="Tobudic S" first="Selma" last="Tobudic">Selma Tobudic</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria selma.tobudic@meduniwien.ac.at.</nlm:affiliation>
<country wicri:rule="url">Autriche</country>
<wicri:regionArea>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32878898</idno>
<idno type="pmid">32878898</idno>
<idno type="doi">10.1136/esmoopen-2020-000889</idno>
<idno type="pmc">PMC7470513</idno>
<idno type="wicri:Area/Main/Corpus">000375</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000375</idno>
<idno type="wicri:Area/Main/Curation">000375</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000375</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.</title>
<author><name sortKey="Fuereder, Thorsten" sort="Fuereder, Thorsten" uniqKey="Fuereder T" first="Thorsten" last="Fuereder">Thorsten Fuereder</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Berghoff, Anna Sophie" sort="Berghoff, Anna Sophie" uniqKey="Berghoff A" first="Anna Sophie" last="Berghoff">Anna Sophie Berghoff</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Heller, Gerwin" sort="Heller, Gerwin" uniqKey="Heller G" first="Gerwin" last="Heller">Gerwin Heller</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Haslacher, Helmuth" sort="Haslacher, Helmuth" uniqKey="Haslacher H" first="Helmuth" last="Haslacher">Helmuth Haslacher</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Laboratory Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Perkmann, Thomas" sort="Perkmann, Thomas" uniqKey="Perkmann T" first="Thomas" last="Perkmann">Thomas Perkmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Laboratory Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Strassl, Robert" sort="Strassl, Robert" uniqKey="Strassl R" first="Robert" last="Strassl">Robert Strassl</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Laboratory Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Berger, Julia Maria" sort="Berger, Julia Maria" uniqKey="Berger J" first="Julia Maria" last="Berger">Julia Maria Berger</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Puhr, Hannah Christina" sort="Puhr, Hannah Christina" uniqKey="Puhr H" first="Hannah Christina" last="Puhr">Hannah Christina Puhr</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kreminger, Judith" sort="Kreminger, Judith" uniqKey="Kreminger J" first="Judith" last="Kreminger">Judith Kreminger</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moik, Florian" sort="Moik, Florian" uniqKey="Moik F" first="Florian" last="Moik">Florian Moik</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schubert, Lorenz" sort="Schubert, Lorenz" uniqKey="Schubert L" first="Lorenz" last="Schubert">Lorenz Schubert</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Starzer, Angelika Martina" sort="Starzer, Angelika Martina" uniqKey="Starzer A" first="Angelika Martina" last="Starzer">Angelika Martina Starzer</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Steindl, Ariane" sort="Steindl, Ariane" uniqKey="Steindl A" first="Ariane" last="Steindl">Ariane Steindl</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Winkler, Stefan" sort="Winkler, Stefan" uniqKey="Winkler S" first="Stefan" last="Winkler">Stefan Winkler</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Preusser, Matthias" sort="Preusser, Matthias" uniqKey="Preusser M" first="Matthias" last="Preusser">Matthias Preusser</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tobudic, Selma" sort="Tobudic, Selma" uniqKey="Tobudic S" first="Selma" last="Tobudic">Selma Tobudic</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria selma.tobudic@meduniwien.ac.at.</nlm:affiliation>
<country wicri:rule="url">Autriche</country>
<wicri:regionArea>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">ESMO open</title>
<idno type="eISSN">2059-7029</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antibodies, Viral (blood)</term>
<term>Austria (epidemiology)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Biomarkers (blood)</term>
<term>Clinical Laboratory Techniques (MeSH)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (transmission)</term>
<term>Coronavirus Infections (virology)</term>
<term>Female (MeSH)</term>
<term>Host-Pathogen Interactions (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Medical Staff, Hospital (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Nursing Staff, Hospital (MeSH)</term>
<term>Oncologists (MeSH)</term>
<term>Oncology Nursing (MeSH)</term>
<term>Oncology Service, Hospital (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Patients (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (transmission)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Predictive Value of Tests (MeSH)</term>
<term>Prospective Studies (MeSH)</term>
<term>Reproducibility of Results (MeSH)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Seroepidemiologic Studies (MeSH)</term>
<term>Serologic Tests (MeSH)</term>
<term>Tertiary Care Centers (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Autriche (épidémiologie)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Centres de soins tertiaires (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (transmission)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Interactions hôte-pathogène (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Mâle (MeSH)</term>
<term>Oncologues (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Patients (MeSH)</term>
<term>Personnel infirmier hospitalier (MeSH)</term>
<term>Personnel médical hospitalier (MeSH)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (transmission)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Reproductibilité des résultats (MeSH)</term>
<term>Service hospitalier d'oncologie (MeSH)</term>
<term>Soins infirmiers en oncologie (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Techniques de laboratoire clinique (MeSH)</term>
<term>Tests sérologiques (MeSH)</term>
<term>Valeur prédictive des tests (MeSH)</term>
<term>Études prospectives (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
<term>Études séroépidémiologiques (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Biomarkers</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Austria</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Autriche</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Clinical Laboratory Techniques</term>
<term>Female</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Staff, Hospital</term>
<term>Middle Aged</term>
<term>Nursing Staff, Hospital</term>
<term>Oncologists</term>
<term>Oncology Nursing</term>
<term>Oncology Service, Hospital</term>
<term>Pandemics</term>
<term>Patients</term>
<term>Predictive Value of Tests</term>
<term>Prospective Studies</term>
<term>Reproducibility of Results</term>
<term>Retrospective Studies</term>
<term>Seroepidemiologic Studies</term>
<term>Serologic Tests</term>
<term>Tertiary Care Centers</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Centres de soins tertiaires</term>
<term>Femelle</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Oncologues</term>
<term>Pandémies</term>
<term>Patients</term>
<term>Personnel infirmier hospitalier</term>
<term>Personnel médical hospitalier</term>
<term>Reproductibilité des résultats</term>
<term>Service hospitalier d'oncologie</term>
<term>Soins infirmiers en oncologie</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Techniques de laboratoire clinique</term>
<term>Tests sérologiques</term>
<term>Valeur prédictive des tests</term>
<term>Études prospectives</term>
<term>Études rétrospectives</term>
<term>Études séroépidémiologiques</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Autriche</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>During the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications for oncological care.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>HCP and patients with cancer at the Division of Oncology, Medical University of Vienna were included between 21 March and 4 June and tested for total antibodies against SARS-CoV-2 employing the Roche Elecsys Anti-SARS-CoV-2 immunoassay. Reactive samples were confirmed or disproved by the Abbott SARS-CoV-2 IgG test. Additionally, a structured questionnaire regarding basic demographic parameters, travel history and COVID-19-associated symptoms had to be completed by HCP.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>146 subjects (62 HCP and 84 patients with cancer) were enrolled. In the oncological HCP cohort, 20 (32.3%) subjects were medical oncologists, 28 (45.2%) nurses at our ward and 14 (22.6%) fulfil other functions such as study coordinators. In the patient cohort, most individuals are on active anticancer treatment (96.4%). 26% of the HCP and 6% of the patients had symptoms potentially associated with COVID-19 since the end of February 2020. However, only in 2 (3.2%) HCP and in 3 (3.6%) patients, anti-SARS-Cov-2 total antibodies were detected. The second assay for anti-SARS-Cov-2 IgG antibodies confirmed the positive result in all HCP and in 2 (2.4%) patients, suggesting an initial assay's unspecific reaction in one case. In individuals with a confirmed test result, an active COVID-19 infection was documented by a positive SARS-CoV-2 RNA PCR test.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Specific anti-SARS-CoV-2 antibodies were found solely in persons after a documented SARS-CoV-2 viral infection, thus supporting the test methods' high sensitivity and specificity. The low prevalence of anti-SARS-CoV-2 antibodies in our cohorts indicates a lack of immunity against SARS-CoV-2. It highlights the need for continued strict safety measures to prevent uncontrolled viral spread among oncological HCPs and patients with cancer.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32878898</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2059-7029</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>ESMO open</Title>
<ISOAbbreviation>ESMO Open</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e000889</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/esmoopen-2020-000889</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">During the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications for oncological care.</AbstractText>
<AbstractText Label="METHODS">HCP and patients with cancer at the Division of Oncology, Medical University of Vienna were included between 21 March and 4 June and tested for total antibodies against SARS-CoV-2 employing the Roche Elecsys Anti-SARS-CoV-2 immunoassay. Reactive samples were confirmed or disproved by the Abbott SARS-CoV-2 IgG test. Additionally, a structured questionnaire regarding basic demographic parameters, travel history and COVID-19-associated symptoms had to be completed by HCP.</AbstractText>
<AbstractText Label="RESULTS">146 subjects (62 HCP and 84 patients with cancer) were enrolled. In the oncological HCP cohort, 20 (32.3%) subjects were medical oncologists, 28 (45.2%) nurses at our ward and 14 (22.6%) fulfil other functions such as study coordinators. In the patient cohort, most individuals are on active anticancer treatment (96.4%). 26% of the HCP and 6% of the patients had symptoms potentially associated with COVID-19 since the end of February 2020. However, only in 2 (3.2%) HCP and in 3 (3.6%) patients, anti-SARS-Cov-2 total antibodies were detected. The second assay for anti-SARS-Cov-2 IgG antibodies confirmed the positive result in all HCP and in 2 (2.4%) patients, suggesting an initial assay's unspecific reaction in one case. In individuals with a confirmed test result, an active COVID-19 infection was documented by a positive SARS-CoV-2 RNA PCR test.</AbstractText>
<AbstractText Label="CONCLUSION">Specific anti-SARS-CoV-2 antibodies were found solely in persons after a documented SARS-CoV-2 viral infection, thus supporting the test methods' high sensitivity and specificity. The low prevalence of anti-SARS-CoV-2 antibodies in our cohorts indicates a lack of immunity against SARS-CoV-2. It highlights the need for continued strict safety measures to prevent uncontrolled viral spread among oncological HCPs and patients with cancer.</AbstractText>
<CopyrightInformation>© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuereder</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Berghoff</LastName>
<ForeName>Anna Sophie</ForeName>
<Initials>AS</Initials>
<Identifier Source="ORCID">0000-0003-0767-6241</Identifier>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Heller</LastName>
<ForeName>Gerwin</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haslacher</LastName>
<ForeName>Helmuth</ForeName>
<Initials>H</Initials>
<Identifier Source="ORCID">0000-0003-4605-2503</Identifier>
<AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perkmann</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Strassl</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Berger</LastName>
<ForeName>Julia Maria</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Puhr</LastName>
<ForeName>Hannah Christina</ForeName>
<Initials>HC</Initials>
<Identifier Source="ORCID">0000-0002-7203-8732</Identifier>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kreminger</LastName>
<ForeName>Judith</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moik</LastName>
<ForeName>Florian</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schubert</LastName>
<ForeName>Lorenz</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Starzer</LastName>
<ForeName>Angelika Martina</ForeName>
<Initials>AM</Initials>
<Identifier Source="ORCID">0000-0001-5867-8461</Identifier>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Steindl</LastName>
<ForeName>Ariane</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Winkler</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Preusser</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<Identifier Source="ORCID">0000-0003-3541-2315</Identifier>
<AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tobudic</LastName>
<ForeName>Selma</ForeName>
<Initials>S</Initials>
<Identifier Source="ORCID">0000-0002-8241-8317</Identifier>
<AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria selma.tobudic@meduniwien.ac.at.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>ESMO Open</MedlineTA>
<NlmUniqueID>101690685</NlmUniqueID>
<ISSNLinking>2059-7029</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000657964">COVID-19 diagnostic testing</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019411" MajorTopicYN="Y">Clinical Laboratory Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008505" MajorTopicYN="Y">Medical Staff, Hospital</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009741" MajorTopicYN="N">Nursing Staff, Hospital</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072103" MajorTopicYN="N">Oncologists</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009859" MajorTopicYN="N">Oncology Nursing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016522" MajorTopicYN="Y">Oncology Service, Hospital</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010361" MajorTopicYN="Y">Patients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012698" MajorTopicYN="Y">Serologic Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D062606" MajorTopicYN="Y">Tertiary Care Centers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">SARS-COV-2</Keyword>
<Keyword MajorTopicYN="Y">healthcare professionals</Keyword>
<Keyword MajorTopicYN="Y">seroprevalence</Keyword>
</KeywordList>
<CoiStatement>Competing interests: TF has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bristol-Myers Squibb, Novartis, Roche, Sanofi, Merck Sharp & Dome, Merck Darmstadt, Amgen, Böhringer-Ingelheim, Accord, AstraZeneca. The following for-profit companies have supported clinical trials and contracted research conducted by TF with payments made to his institution: Bristol-Myers Squibb, Merck Sharp & Dome, Roche, Merck Darmstadt. ASB has research support from Daiichi Sankyo (≤€10 000), Roche (>€10 000) and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo (all <€5000) as well as travel support from Roche, Amgen and AbbVie. ASB has research support from Daiichi Sankyo (≤€10 000), Roche (>€10 000) and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo (all <€5000) as well as travel support from Roche, Amgen and AbbVie. MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to his institution: Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie. GH, TP, RS, JB, HCP, JK, FM, LS, AMS, AS, SW and ST have nothing to disclose.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>08</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32878898</ArticleId>
<ArticleId IdType="pii">esmoopen-2020-000889</ArticleId>
<ArticleId IdType="doi">10.1136/esmoopen-2020-000889</ArticleId>
<ArticleId IdType="pmc">PMC7470513</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32584464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Jun 20;395(10241):1919-1926</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32473682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2020 Aug;31(8):1087-1088</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):778-785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32198501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Mar 26;368:m1254</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217525</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):265-269</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Sep;81(3):420-426</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32504745</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Natl Compr Canc Netw. 2020 Mar 20;:1-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32197238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Immunol Infect. 2020 May 15;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32425996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ESMO Open. 2020 Jul;5(Suppl 3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32669298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Sep;26(9):1494</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32812013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Invest. 2020 Sep;50(9):e13315</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32535890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 16;323(23):2425-2427</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32421144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2020 Jan;25(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31992387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Sep;20(9):1051-1060</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32539986</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Aug;26(8):1200-1204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biopreserv Biobank. 2018 Dec;16(6):477-482</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30335475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Aug 1;396(10247):313-319</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32534626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Oncol Rep. 2020 May 8;22(5):53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32385672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JCO Oncol Pract. 2020 Jun 23;:OP2000297</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32574131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2020 Aug 14;:JCO2001442</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32795227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 May;94:44-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ESMO Open. 2020 Apr;5(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32295769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Aug 18;173(4):262-267</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32422057</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ESMO Open. 2020 Mar;5(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32229501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diagnostics (Basel). 2020 May 19;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32438677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):747-756</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196430</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000375 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000375 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidSeniorV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32878898
   |texte=   SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:32878898" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidSeniorV1

This area was generated with Dilib version V0.6.37.
Data generation: Thu Oct 15 09:49:45 2020. Site generation: Wed Jan 27 17:10:23 2021

	Serveur d'exploration sur la COVID chez les séniors
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID chez les séniors

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki